Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855465 | 0.81 | APLNR (0.38) | APLNR | |
| SCHEMBL13732902 | 0.80 | APLNR (0.41) | APLNR | |
| SCHEMBL15339551 | 0.78 | APLNR (0.39) | APLNR | |
| SCHEMBL21701327 | 0.76 | APLNR (0.38) | APLNR | |
| SCHEMBL25139132 | 0.75 | APLNR (0.37) | APLNR | |
| SCHEMBL19814825 | 0.75 | APLNR (0.37) | APLNR | |
| SCHEMBL21123498 | 0.73 | APLNR (0.35) | APLNR | |
| SCHEMBL16266677 | 0.73 | APLNR (0.35) | APLNR | |
| SCHEMBL21855470 | 0.72 | APLNR (0.34) | APLNR | |
| SCHEMBL20627260 | 0.72 | APLNR (0.34) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626546-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-12435054-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240300946-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
| CN-117940424-A | EGFR inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2022271630-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4081515-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | Blueprint Medicines Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2021150806-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021133809-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133809-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021108483-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | APLNR 4507/4885 |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | APLNR 1654/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | APLNR 1875/4885 |
| US-12435054-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | APLNR 1654/4885 |
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | APLNR 1832/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | APLNR 4507/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | APLNR 1875/4885 |
| US-20240300946-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | APLNR 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.